Superworth

Envista price to free cash flow NVST

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Nov 2, 2026
16.0×
6-year median
19.1×
Against its 6-year history
33rd
percentile: 0 is its lowest day, 100 its highest
6-year range
8.6× to 62.4×
Peer median
24.8×

Envista's price to free cash flow is 16.0× as of Nov 2, 2026.

That is below its 6-year median of 19.1×, lower than on 67% of days in the last 6 years.

Over that time it ranged from 8.6× in Apr 2025 to 62.4× in Mar 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 24.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.0×13.6×20.8×
202513.8×8.6×14.0×
202412.1×9.7×19.2×
202319.0×17.0×62.4×
202239.0×19.0×44.0×
202120.2×14.7×29.9×
202023.7×18.6×25.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Envista's size, closest first, today.

CompanyPrice to free cash flow
NVSTEnvista16.0×
ICUIICU Medical26.6×
BMIBadger Meter31.6×
VNTVontier12.9×
MMSIMerit Medical Systems24.8×
ATRCAtriCure57.3×
WRBYWarby Parker136×
HAEHaemonetics18.8×
UFPTUFP Technologiesn/m
MSAMSA Safety20.3×
INSPInspire Medical Systems16.6×
Peer median24.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Envista

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.